Recently, the combination of atezolizumab (anti programmed death-ligand 1 [PD-L1]) and bevacizumab (anti–vascular endothelial growth factor [VEGF]) combination was approved as a first-line treatment for advanced HCC with superiority for sorafenib [46]. Here, VEGFA is linked to hepatocellular carcinoma.